Tempest Therapeutics Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Tempest Therapeutics şirketinin kazançlarının yıllık 14.5% oranında düşmesi, yıllık gelirinin ise yıllık 66.9% oranında artması bekleniyor. EPS'nin yıllık 6.5% oranında büyümesi bekleniyor.

Anahtar bilgiler

-14.5%

Kazanç büyüme oranı

6.5%

EPS büyüme oranı

Biotechs kazanç büyümesi	28.3%
Gelir büyüme oranı	66.9%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Low
Son güncelleme	20 Nov 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Tempest Therapeutics GAAP EPS of -$0.79

Aug 15

Tempest Therapeutics CEO Stephen Brady - Small Molecule Cancer Treatment

Jan 04

Kazanç ve Gelir Büyüme Tahminleri

NasdaqCM:TPST - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	N/A	-62	N/A	-52	4
12/31/2025	N/A	-47	N/A	-37	5
12/31/2024	N/A	-38	N/A	-33	5
9/30/2024	N/A	-36	-29	-29	N/A
6/30/2024	N/A	-32	-26	-25	N/A
3/31/2024	N/A	-30	-27	-26	N/A
12/31/2023	N/A	-29	-28	-27	N/A
9/30/2023	N/A	-31	-28	-28	N/A
6/30/2023	N/A	-33	-31	-30	N/A
3/31/2023	N/A	-35	-33	-32	N/A
12/31/2022	N/A	-36	-32	-31	N/A
9/30/2022	N/A	-34	-33	-33	N/A
6/30/2022	N/A	-34	-35	-35	N/A
3/31/2022	N/A	-31	-27	-27	N/A
12/31/2021	N/A	-28	-26	-26	N/A
9/30/2021	N/A	-25	-22	-22	N/A
6/30/2021	N/A	-22	-15	-15	N/A
3/31/2021	N/A	-20	-20	-20	N/A
12/31/2020	N/A	-19	-19	-19	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: TPST önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: TPST önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: TPST önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: TPST gelecek yıl gelir elde edemeyeceği tahmin ediliyor.

Yüksek Büyüme Geliri: TPST gelecek yıl gelir elde edemeyeceği tahmin ediliyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: TPST 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Tempest Therapeutics Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Price target increased by 26% to US$19.67

Price target decreased by 18% to US$15.67

Price target increased by 16% to US$19.00

Recent updates

New major risk - Financial position

Tempest Therapeutics, Inc. Receives FDA Study May Proceed for Pivotal Phase 3 Trial of Amezalpat Combination Therapy for the Treatment of First-Line Hepatocellular Carcinoma

Insufficient new directors

Tempest Announces Successful End-Of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma

New major risk - Share price stability

New major risk - Financial position

CEO, President & Director recently bought US$74k worth of stock

Tempest Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $205 million.

Tempest Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $205 million.

New major risk - Share price stability

New major risk - Revenue and earnings growth

High number of new and inexperienced directors

Tempest Therapeutics, Inc., Annual General Meeting, Jun 13, 2024

Tempest Therapeutics, Inc. Reports New Preclinical Data for TPST-1120 in RCC At the AACR Annual Meeting

Tempest Therapeutics, Inc. Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications

Tempest Therapeutics, Inc. Presents New Data At the SITC 2024 Spring Scientific Meeting Supporting Potent Anti-Tumor Activity of TPST-1120 in Multiple Cancer Types

New major risk - Shareholder dilution

New major risk - Negative shareholders equity

Price target increased by 26% to US$19.67

Tempest Therapeutics, Inc. Releases New Data Demonstrating Superiority of TPST-1120 Arm Across Multiple Study Endpoints in Randomized First-Line HCC Study

Tempest Therapeutics, Inc. Announces Expanded Role for Sam Whiting as Chief Medical Officer and Head of Research and Development

High number of new and inexperienced directors

Tempest Therapeutics, Inc. Receives Non-Compliance Letter from Nasdaq

Tempest Therapeutics, Inc. Receives Non-Compliance Letter from Nasdaq

Tempest Therapeutics, Inc. Announces Executive Changes

Price target decreased by 18% to US$15.67

New major risk - Market cap size

Tempest Therapeutics, Inc. to Present Phase 1 Monotherapy and Combination Data at ASCO for TPST-1495 in Patients with Advanced Cancers

Price target increased by 16% to US$19.00

No independent directors

Tempest Therapeutics, Inc. Announces Executive Changes

Tempest Therapeutics GAAP EPS of -$0.79

Tempest Therapeutics Inc. Reports Positive TPST-1120 Clinical Data from Phase 1 Trial in Patients with Advanced Solid Tumors

Tempest Therapeutics, Inc., Annual General Meeting, Jun 17, 2022

No independent directors

Tempest Therapeutics CEO Stephen Brady - Small Molecule Cancer Treatment

Director Brett I. Zbar has left the company

Director Keting Chu has left the company

Director Jiaxin Li has left the company

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin